MSB 3.76% $1.03 mesoblast limited

Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-391

  1. 8,868 Posts.
    lightbulb Created with Sketch. 6635
    Yes indeed a very appalling decision from the FDA , they will have to deal with that together with the very serious conflict of interest sooner than you think , while I think the FDA would not have expected this stance from MSB ?I can imagine MSB would have said , sorry we have more pressing and important trials to deal with at this time and that the FDA GVHD decision will have to rest on their heads , its not over yet MSB'ers when the FDA makes a very obvious stupid decision that will kill children with GVHD, heads will roll.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.03
Change
-0.040(3.76%)
Mkt cap ! $1.170B
Open High Low Value Volume
$1.07 $1.07 $1.01 $13.19M 12.81M

Buyers (Bids)

No. Vol. Price($)
3 61090 $1.02
 

Sellers (Offers)

Price($) Vol. No.
$1.03 239558 5
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.